Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.50 |
| ▸ | OGA | O60502 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2072892 | 0.87 | OGA (0.48) | HRH4OGAHRH3HDAC3HDAC1 | |
| SCHEMBL2075168 | 0.83 | HRH4 (0.46) | HRH4OGAHRH3SHMT2CXCR4 | |
| SCHEMBL2075511 | 0.79 | HRH4 (0.48) | HRH4OGAHRH3SHMT2ALDH1A1 | |
| SCHEMBL2076140 | 0.78 | OGA (0.47) | HRH4OGAHRH3SMN1; SMN2ADORA1 | |
| SCHEMBL2074448 | 0.78 | IDH1 (0.48) | HRH4OGASHMT2CXCR4ALDH1A1 | |
| SCHEMBL2074665 | 0.77 | KDM4E (0.46) | HRH4OGAHRH3MAPTALDH1A1 | |
| SCHEMBL2075468 | 0.75 | EGFR (0.48) | HRH4HRH3SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL4197090 | 0.75 | HRH3 (0.46) | HRH4OGAHRH3 | |
| SCHEMBL2074918 | 0.72 | HRH3 (0.69) | HRH4OGAHRH3 | |
| SCHEMBL19116507 | 0.70 | SMN1; SMN2 (0.48) | SMN1; SMN2ADORA1MAPTGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902184-B2 | Piperazinyl pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20070281921-A1 | Piperidinyl pyrimidine derivatives | HOFFMAN-LA ROCHE INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281921-A1 | Piperidinyl pyrimidine derivatives | HRH2, P2RX5, P2RX3 | HRH4 4/4885OGA 4644/4885HRH3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.